Compare ASMB & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASMB | DIAX |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.8M | 561.9M |
| IPO Year | 2010 | N/A |
| Metric | ASMB | DIAX |
|---|---|---|
| Price | $27.84 | $15.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $43.40 | N/A |
| AVG Volume (30 Days) | ★ 109.9K | 96.6K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,191,000.00 | N/A |
| Revenue This Year | $33.33 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.30 | N/A |
| 52 Week Low | $7.75 | $12.80 |
| 52 Week High | $39.71 | $15.12 |
| Indicator | ASMB | DIAX |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 54.72 |
| Support Level | $25.93 | $15.23 |
| Resistance Level | $32.31 | $15.67 |
| Average True Range (ATR) | 1.74 | 0.17 |
| MACD | -0.43 | -0.02 |
| Stochastic Oscillator | 25.06 | 48.94 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.